글로벌 연구동향
방사선종양학
- 2018년 11월호
[Radiother Oncol.] Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.연세의대 / 김현주, 성진실*
- 출처
- Radiother Oncol.
- 등재일
- 2018 Oct
- 저널이슈번호
- 129(1):130-135. doi: 10.1016/j.radonc.2017.11.027. Epub 2018 Jan 30.
- 내용
Abstract
PURPOSE:
To investigate the clinical implications of the soluble programmed cell death-ligand 1 (sPD-L1) level in hepatocellular carcinoma (HCC) patients treated with radiotherapy (RT).MATERIALS/METHODS:
HCC patients treated with RT between June 2011 and March 2015 were prospectively recruited and sPD-L1 levels were measured using an enzyme-linked immunosorbent assay. Blood samples were obtained at the RT start, RT end, and 1-month follow-up. The associations of the sPD-L1 level with the clinical features and outcomes were analyzed.RESULTS:
Fifty-three patients with HCC were included. Thirty-four patients received conventional fractionated RT with hepatic arterial infusional chemotherapy, while 19 patients received stereotactic body radiotherapy (SBRT). The initial sPD-L1 level was significantly associated with stage, tumor size, portal vein tumor thrombosis, and venous invasion. The overall-survival was significantly poorer in patients with a higher level of initial sPD-L1 (≥1.315 pg/mL). A higher level of sPD-L1 at 1 month (≥12.9 pg/mL) was significantly related to early lung metastasis. The sPD-L1 level was significantly increased after RT and the change pattern of sPD-L1 was different between two RT schemes.CONCLUSIONS:
The level of sPD-L1 was associated with tumor aggressiveness and outcomes, suggesting its role as a possible predictive biomarker. The increases in sPD-L1 after RT suggests that combined treatment with RT and immune checkpoint inhibitors may be a promising therapeutic strategy in HCC.
Author informationKim HJ1, Park S1, Kim KJ1, Seong J2.
1
Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
2
Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: jsseong@yuhs.ac.
- 키워드
- Hepatocellular carcinoma; Immune checkpoint inhibitor; Radiotherapy; Soluble PD-L1
- 덧글달기
- 이전글 [Radiother Oncol.] Lung dose and the potential risk of death in postoperative radiation therapy for non-small cell lung cancer: A study using the method of stratified grouping.
- 다음글 [Clin Breast Cancer.] Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
편집위원
간암으로 방사선치료를 받은 환자에서 sPD-L1의 임상적 의의를 분석함. 특히 sPD-L1의 반응이 CCRT와 SBRT 간에 다른 부분이 흥미로움.
덧글달기닫기2018-11-14 15:48:22
등록
편집위원2
Immune checkpoint inhibitor를 이용한 임상연구가 활발히 진행되는 간세포암종에서 방사선치료 전후 전향적으로 혈액샘플을 채취하여 sPD-1 level과 변화양상을 비교하고 생존율 분석까지 진행했다는 면에서 선도적인 연구로 생각됩니다.
덧글달기닫기2018-11-14 15:49:13
등록